IL17A and rheumatoid arthritis: However, we cannot exclude that inhibition of Th17 function is not the main therapeutic mechanism of At’s decoction; regardless, the potential use of IL-17 mAbs in conjunction with inhibitors of other Th17-specific mediators to treat RA warrants further study.